Research programme: CRE-decoy aptamers - Genta

Drug Profile

Research programme: CRE-decoy aptamers - Genta

Alternative Names: Research programme: decoy aptamers - Genta

Latest Information Update: 09 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Institutes of Health (USA)
  • Class
  • Mechanism of Action Genetic transcription modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 11 Sep 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 02 Jun 2006 This programme is still in active development
  • 04 Mar 2003 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top